JASON ROBERT WESTIN to Antibodies, Monoclonal
This is a "connection" page, showing publications JASON ROBERT WESTIN has written about Antibodies, Monoclonal.
Connection Strength
0.331
-
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77.
Score: 0.191
-
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 09; 16(9):483-487.
Score: 0.057
-
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy. Leuk Lymphoma. 2010 Jan; 51(1):161-3.
Score: 0.036
-
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep. 2009 Oct; 4(4):218-24.
Score: 0.036
-
Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56.
Score: 0.012